<DOC>
	<DOC>NCT02143570</DOC>
	<brief_summary>Overactive bladder is a common problem among adult women. Darifenacin is an antimuscarinic drug that is frequently used as part of the management of the condition. However, current evidence backing its use is limited. This study aims to address Darifenacin's effectiveness in adjunct to physiotherapy in treating symptoms due to overactive bladder.</brief_summary>
	<brief_title>Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Darifenacin</mesh_term>
	<criteria>Patients with overactive bladder as diagnosed and confirmed by a urologist. Able to answer the ICIC, King's Health Questionnaire and Overactive Bladder Questionnaire. Able and willing to receive urodynamic studies. History of pelvic radiotherapy. Recent pelvic surgery (&lt;1 year). History of antiincontinence surgery. Pregnancy.</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Urinary Bladder, Overactive</keyword>
	<keyword>Darifenacin</keyword>
	<keyword>Physiotherapy</keyword>
	<keyword>Quality of Life</keyword>
</DOC>